| Previous Close | 49.00 |
| Open | 48.91 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 48.50 - 53.00 |
| 52 Week Range | 34.07 - 57.50 |
| Volume | 11,793 |
| Avg. Volume | 12,401 |
| Market Cap | 346.049M |
| Beta (5Y Monthly) | 1.29 |
| PE Ratio (TTM) | 31.12 |
| EPS (TTM) | 1.70 |
| Earnings Date | Mar 02, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 71.50 |
Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2019 after the close of U.S. financial markets on Tuesday, March 3, 2020. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day. Andrew Weinstein, senior vice president, finance and accounting, and Dennis Rosenberg, chief marketing officer, will join him on the call.
Q3 2019 Semler Scientific Inc Earnings Call
2019 Q3 HIGHLIGHTS compared to the corresponding period of 2018: - Revenues were $8,902,000 , an increase of 60% - Pre-tax income of $3,108,000 , an increase of $1,640,000 , or 112%, compared to $1,468,000 ...
SAN JOSE, Calif. , Oct. 23, 2019 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency ...
The company did not hold an earnings call as CEO Doug Murphy-Chutorian continues to recover from the mild stroke he suffered approximately six weeks prior. Encouragingly, the Q2 earnings release notes that Doug continues to make strong progress, that SMLR will host a Q3 earnings call and that additional executives will join him on the call. As it relates to Q2 results, pretty much the whole income statement was a highlight.
2019 Q2 HIGHLIGHTS compared to the corresponding period of 2018: - Revenues were $7,953,000 , an increase of 45% - Net income grew to $0.41 per basic share and $0.32 per diluted share, compared to $0.24 ...
SAN JOSE, Calif., July 16, 2019 /PRNewswire/ -- Semler Scientific, Inc. (SMLR), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the second quarter and first half ended June 30, 2019 before the open of U.S. financial markets on Friday, July 26, 2019. Semler will not host an investor call for this quarter as Chief Executive Officer, Doug Murphy-Chutorian, M.D. continues his recovery from a mild stroke. Semler anticipates that it will host a conference call to discuss financial results for the third quarter and first nine months of 2019.
On June 17th, Semler (SMLR) announced that while CEO Doug Murphy-Chutorian suffered a mild stroke following elective surgery, he continues to lead the company and the incident did not result in any interruptions to the business. As such, we continue to reiterate our comments from our recent earnings updates… the consistency and regularity of revenue growth and flatness of expenses lend credence to the validity of the company’s business model and strategy. Much of that hinges on the supposition that insurers have an economic interest in paying for their capitation-based insured to be tested for PAD.
SAN JOSE, Calif. , June 17, 2019 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency ...
Meanwhile, operating expenses (not including cost of revenue) were at an all-time high but inline with our $4.0M estimate and a record low on a percentage of sales basis. Perhaps just as important as the new records that were set on the top and bottom lines was that significant cash generation continues (Q1 cash flow statement will be available when the 10-Q is filed). Semler generated positive cash flow from operations in every quarter in 2018.
2019 Q1 HIGHLIGHTS compared to the corresponding period of 2018: - Revenue was $6,761,000 , which is an increase of 51% - Net income grew to $0.29 per basic share and $0.23 per diluted share, compared ...
SAN JOSE, Calif. , April 18, 2019 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency ...
Q4 2018 Results: Revenue, Earnings & Cash Flow Continue to Climb. Semler (SMLR) reported financial results for the fourth quarter ending December 31, 2018. While revenue slightly missed our estimate, it nonetheless came in strong – up 42% yoy, 7% better than Q3 and a new record high.